The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Kivexa abacavir;lamivudine | ViiV Healthcare BV | HIV Infections | 🇪🇺 EU 2004-12-16 | Order → |
| Xagrid anagrelide | Takeda Pharmaceuticals International AG Ireland | Thrombocythemia, Essential | 🇪🇺 EU 2004-11-15 | Order → |
| Emselex darifenacin hydrobromide | pharmaand GmbH | Urinary Incontinence, Urge; Urinary Bladder, Overactive | 🇪🇺 EU 2004-10-22 | Order → |
| Mimpara cinacalcet | Amgen Europe B.V. | Hypercalcemia; Parathyroid Neoplasms; Hyperparathyroidism | 🇪🇺 EU 2004-10-22 | Order → |
| Parareg cinacalcet | Dompé Biotec S.p.A. | Hypercalcemia; Parathyroid Neoplasms; Hyperparathyroidism | 🇪🇺 EU 2004-10-22 | Order → |
| Wilzin zinc | Recordati Rare Diseases | Hepatolenticular Degeneration | 🇪🇺 EU 2004-10-12 | Order → |
| Apidra insulin glulisine | sanofi-aventis Deutschland GmbH | Diabetes Mellitus | 🇪🇺 EU 2004-09-27 | Order → |
| Alimta pemetrexed | Eli Lilly Nederland B.V. | Mesothelioma; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2004-09-20 | Order → |
| Angiox bivalirudin | The Medicines Company UK Ltd | Acute Coronary Syndrome | 🇪🇺 EU 2004-09-20 | Order → |
| Osseor strontium ranelate | Les Laboratoires Servier | Osteoporosis, Postmenopausal | 🇪🇺 EU 2004-09-20 | Order → |
| Protelos strontium ranelate | Les Laboratoires Servier | Osteoporosis, Postmenopausal | 🇪🇺 EU 2004-09-20 | Order → |
| Raptiva efalizumab | Serono Europe Limited | Psoriasis | 🇪🇺 EU 2004-09-20 | Order → |
| Ariclaim duloxetine | Eli Lilly Nederland B.V. | Diabetic Neuropathies | 🇪🇺 EU 2004-08-11 | Order → |
| Yentreve duloxetine | Eli Lilly Nederland B.V. | Urinary Incontinence, Stress | 🇪🇺 EU 2004-08-11 | Order → |
| Pedea ibuprofen | Recordati Rare Diseases | Ductus Arteriosus, Patent | 🇪🇺 EU 2004-07-28 | Order → |
| Telzir fosamprenavir | ViiV Healthcare BV | HIV Infections | 🇪🇺 EU 2004-07-12 | Order → |
| Lyrica pregabalin | Viatris EESV | Epilepsy; Anxiety Disorders; Neuralgia | 🇪🇺 EU 2004-07-05 | Order → |
| Erbitux cetuximab | Merck Europe B.V. | Head and Neck Neoplasms; Colorectal Neoplasms | 🇪🇺 EU 2004-06-29 | Order → |
| Kentera (previously Oxybutynin Nicobrand) oxybutynin | Teva B.V. | Urinary Incontinence, Urge | 🇪🇺 EU 2004-06-15 | Order → |
| TachoSil human fibrinogen;human thrombin | Corza Medical GmbH | Hemostasis, Surgical | 🇪🇺 EU 2004-06-08 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.